Racial/ethnic disparities in initiation and persistent use of anti-dementia medications.
Alzheimers Dement
; 18(12): 2582-2592, 2022 12.
Article
em En
| MEDLINE
| ID: mdl-35218291
ABSTRACT
BACKGROUND:
Racial/ethnic disparities in anti-dementia medications use in longitudinally followed research participants are unclear.METHODS:
The study included initially untreated participants followed in National Alzheimer's Coordinating Center Uniform Data Set who were ≥65 at baseline with Alzheimer's disease dementia.OUTCOMES:
Outcomes for acetylcholinesterase inhibitor (AChEI) treatment included (1) any new AChEI treatment during follow-up, and (2) persistence of treatment during follow-up categorized into intermittent treatment (< 50% follow-ups reporting treatment), persistent (≥50% follow-ups), and always treated. Outcomes for memantine treatment were similarly constructed.RESULTS:
Controlling for participant characteristics, Black and Hispanic participants remained less likely than White participants to report any new AChEI or memantine treatment during follow-up. Among those who reported new treatment during follow-up, both Black and Hispanic participants were less likely than White participants to be persistently treated with AChEI and memantine.DISCUSSION:
Substantial racial/ethnic treatment disparities remain in controlled settings of longitudinal research in which participants have access to dementia experts, suggesting wider disparities in the larger community.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Memantina
/
Doença de Alzheimer
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article